Tigermed (Stock code: 300347.SZ/3347.HK) is a leading provider of innovative clinical research solutions across the full life cycle of biopharmaceutical and medical device products globally. With a broad portfolio of services and a promise of quality, from clinical development to commercialization, we are committed to moving our customers and patients through their development journey efficiently and cost-effectively. Tigermed currently represents a worldwide network of more than 80 subsidiaries and 170 offices and sites, with over 8,600 employees across 51 countries in Asia Pacific, Europe, North & South America and Africa. We are devoted to building an integrated platform that enables boundless possibility for healthcare industry, embracing challenges to fulfill our commitment to serve unmet patients' needs, and eventually saving lives.
解锁市场时间线与信号动态
最近 90 天内有 8 个信号。
该公司进入各个市场的顺序 — 从最早到最新
Senior Project Manager/Project Director (Clinical Operation)-Taiwan
Clinical Project Manager
注册以查看完整信号动态
Tigermed 的国际扩张与竞争对手的对比情况
Tigermed你条形图显示所对比公司之间的相对规模。
列5| 公司 | 市场 | 新市场 | 势头 | 活动 | 扩张评分 |
|---|---|---|---|---|---|
 Tigermed你 | 6 | 1 | +67% | 8 | 33 |
Clinical Project Manager_Taiwan Base_Support Australia
查看职位Taiwan · 昨天
Contractor Project Manager
查看职位Australia · 昨天
RA Specialist_Turkey
查看职位Türkiye · 前天
没有进行中的营销活动
注册以跟踪该公司，并在发生变化时第一时间获得提醒。
启明创投支持的英矽智能在港交所上市，成为2025年最大生物科技IPO，市值195.1亿港元。该AI驱动的药物研发公司致力于延长人类健康寿命。
启明创投周志峰位列福布斯2026年全球最佳创投人榜第80位,为首位上榜中国科技AI投资人。其投资组合包括壁仞科技、智谱等AI企业。
启明创投管理合伙人周志峰首次登上福布斯2026年全球最佳创投人榜第80位,凭借其在人工智能和科技领域的投资成就,2026年已有四家投资组合公司上市。
解锁已验证邮箱与直拨电话
免费 · 无需信用卡
关于 Tigermed 的业务、市场和增长信号的快速解答。
